At the JPM conference, Pfizer CEO Albert Bourla projected optimism, saying the market was overlooking the pharma company's ...

The metaverse hype is over, but developer Cassette Group has been working with Pfizer to realise its forgotten potential.

U.S. drugmaker Pfizer is going "all in" to develop its experimental obesity drug and has been recruiting more experts in that ...

While presenting at the JP Morgan Healthcare Conference, Pfizer Inc. (NYSE:PFE) Albert Bourla, Chairman and CEO, said, “I ...

Pfizer (PFE.N), opens new tab will sell shares worth 2.50 billion pounds ($3.05 billion) in Haleon (HLN.L), opens new tab, lowering its stake in the British consumer healthcare company to about 7. ...

Monday, three Big Pharma leaders took center stage and addressed concerns about future patent expirations head-on.

On the face of it, Pfizer's ROE is not much to talk about. A quick further study shows that the company's ROE doesn't compare ...

Analyst Evan Seigerman from BMO Capital maintained a Buy rating on Pfizer (PFE – Research Report) and keeping the price target at $36.00.Stay ...

Pfizer Inc. sold about 700 million shares in Haleon Plc, further paring its stake in the maker of Sensodyne toothpaste.Most ...

Citi analyst Geoff Meacham maintained a Hold rating on Pfizer (PFE – Research Report) today. The company’s shares closed yesterday at ...

Trump’s attorney general selection Pam Bondi is worth $12.2 million, nearly $3 million of which is held in Trump Media shares ...

Bourla said the experts were helping Pfizer "make better and more sound decisions," and the company could start a late-stage study of its drug, danuglipron, in the second half of this year.